Tag

#oxbryta

Articles

2 articles

MTS HighlightsJanuary 10, 2025
MTS: 2024 Performance Highlights
As we reflect on 2024, we’re proud to celebrate an incredible year of growth, impact, and success at Mass Tort Strategies (MTS). Thanks to the dedication of our skilled intake team and strong partnerships with law firms, we’ve achieved remarkable milestones in delivering high-quality, responsive cases to our partners. Here’s what we accomplished in 2024:
Mass Tort Trends & UpdatesDecember 27, 2024
Oxbryta Lawsuit Updates
Oxbryta (voxelotor), a medication developed to treat sickle cell disease (SCD), has recently become the focus of significant legal action following its global recall in September 2024. Manufactured by Pfizer, Oxbryta was initially hailed as a breakthrough treatment for SCD, a genetic disorder characterized by abnormal hemoglobin that leads to distorted, sickle-shaped red blood cells.

Let's get started